KEY PREDICTIVE FACTORS OF AXITINIB (AG-013736)-INDUCED PROTEINURIA AND EFFICACY: A JAPANESE PHASE II STUDY IN PATIENTS WITH CYTOKINE-REFRACTORY METASTATIC RENAL CELL CANCER (MRCC)

被引：0
|
作者：
Tomita, Y. [1 ]
Uemura, H. [2 ]
Fujimoto, H. [3 ]
Kanayama, H. [4 ]
Shinohara, N. [5 ]
Nakazawa, H. [6 ]
Ozono, S. [7 ]
Naito, S. [8 ]
Akaza, H. [9 ]
机构：
[1] Yamagata Univ, Sch Med, Yamagata 99023, Japan
[2] Kinki Univ, Sch Med, Osaka 589, Japan
[3] Natl Canc Ctr, Tokyo, Japan
[4] Univ Tokushima, Fac Med, Tokushima 770, Japan
[5] Hokkaido Univ Hosp, Sapporo, Hokkaido 060, Japan
[6] Tokyo Womens Med Univ, Med Ctr E, Tokyo, Japan
[7] Hamamatsu Univ Sch Med, Hamamatsu, Shizuoka 4312102, Japan
[8] Kyushu Univ Hosp, Fukuoka 812, Japan
[9] Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：282 / 282
页数：1
相关论文
共 50 条
  • [1] Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma
    Tomita, Yoshihiko
    Uemura, Hirotsugu
    Fujimoto, Hiroyuki
    Kanayama, Hiro-omi
    Shinohara, Nobuo
    Nakazawa, Hayakazu
    Imai, Keiji
    Umeyama, Yoshiko
    Ozono, Seiichiro
    Naito, Seiji
    Akaza, Hideyuki
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (17) : 2592 - 2602
  • [2] Axitinib (AG-013736) in patients with metastatic melanoma: A phase II study
    Fruehauf, J. P.
    Lutzky, J.
    McDermott, D. F.
    Brown, C. K.
    Pithavala, Y. K.
    Bycott, P. W.
    Shalinsky, D.
    Liau, K. F.
    Niethammer, A.
    Rixe, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] LEVOTHYROXIN TREATMENT OF HYPOTHYROIDISM AND AXITINIB (AG-013736) EFFICACY IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Dutcher, J. P.
    Rixe, O.
    Motzer, R. J.
    Wilding, G.
    Stadler, W. M.
    Kim, S.
    Tarazi, J.
    Rosbrook, B.
    Rini, B.
    ANNALS OF ONCOLOGY, 2008, 19 : 194 - 194
  • [4] Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib
    Rini, B. I.
    Wilding, G. T.
    Hudes, G.
    Stadler, W. M.
    Kim, S.
    Tarazi, J. C.
    Bycott, P. W.
    Liau, K. F.
    Dutcher, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study
    Rixe, Olivier
    Bukowski, Ronald M.
    Michaelson, M. Dror
    Wilding, George
    Hudes, Gaty R.
    Bolte, Oliver
    Motzer, Robert J.
    Bycott, Paul
    Liou, Katherine F.
    Freddo, James
    Trask, Peter C.
    Kim, Sinil
    Rini, Brian I.
    LANCET ONCOLOGY, 2007, 8 (11): : 975 - 984
  • [6] Axitinib (AG-013736; AG) in patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sorafenib
    Rini, B.
    Wilding, G.
    Hudes, G.
    Stadler, W. M.
    Kim, S.
    Tarazi, J.
    Bycott, P.
    Liau, K.
    Dutcher, J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 300 - 300
  • [7] Axitinib Treatment in Patients With Cytokine-Refractory Metastatic Renal Cell Cancer
    Rixe, O.
    Bukowski, R. M.
    Michaelson, M. D.
    CURRENT ONCOLOGY REPORTS, 2009, 11 (02) : 81 - 83
  • [8] Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer
    Ronald M. Bukowski
    Current Oncology Reports, 2009, 11 : 81 - 83
  • [9] A PHASE II STUDY OF S-1 IN PATIENTS (PTS) WITH CYTOKINE-REFRACTORY METASTATIC RENAL CELL CANCER (MRCC)
    Naito, S.
    Akaza, H.
    Usami, M.
    Tsukamoto, T.
    Shinohara, N.
    Tomita, Y.
    Namiki, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 190 - 190
  • [10] DISEASE-RELATED SYMPTOMS OF KIDNEY CANCER IN SORAFENIB-REFRACTORY METASTATIC RENAL CELL CANCER (MRCC) PATIENTS (PTS) TREATED WITH AXITINIB (AG-013736)
    Trask, P. C.
    Mardekian, J.
    Tarazi, J.
    Bycott, P.
    Kim, S.
    Dutcher, J. P.
    Wilding, G.
    Hudes, G. R.
    Stadler, W. M.
    Rini, B.
    ANNALS OF ONCOLOGY, 2008, 19 : 192 - 192
12345